Skip to content
Triangle logo TriangleGet started
← Full study record

NCT01012492 · OUTCOME

Hematologic and Immunologic Reconstitution

Pilot of Abatacept-based Immunosuppression for Prevention of Acute GvHD During Unrelated Donor HCT · Source last updated 2019-11-21

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure
MEAN
Unit
cell per microlitre
Interval / dispersion
Standard Error
Time frame
Day +100 post-transplant

What was measured

Flow cytometric analysis of CD4 t-cell t-cell reconstitution was performed at day +100 post-transplant.

Groups in this outcome

Abatacept

Participants will receive one of two standard myeloablative conditioning regimens for their stem cell transplant, and will receive an aGvHD prophylaxis regimen including cyclosporine, methotrexate, and abatacept. Abatacept: Participants will receive one of two standard myeloablative conditioning regimens for their stem cell transplant, and will receive an aGvHD prophylaxis regimen including cyclosporine, methotrexate, and abatacept.

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

GroupSource count
Abatacept10

Reported measurements

Source class 1
Values in cell per microlitre · Interval/dispersion: Standard Error
GroupValueSpreadLowerUpperComment
Abatacept285105Not reportedNot reportedNot reported
Complete source fields
classes
  1. categories
    1. measurements
      1. group Id
        OG000
        spread
        105
        value
        285
denoms
  1. counts
    1. group Id
      OG000
      value
      10
    units
    Participants
description
Flow cytometric analysis of CD4 t-cell t-cell reconstitution was performed at day +100 post-transplant.
dispersion Type
Standard Error
groups
  1. description
    Participants will receive one of two standard myeloablative conditioning regimens for their stem cell transplant, and will receive an aGvHD prophylaxis regimen including cyclosporine, methotrexate, and abatacept. Abatacept: Participants will receive one of two standard myeloablative conditioning regimens for their stem cell transplant, and will receive an aGvHD prophylaxis regimen including cyclosporine, methotrexate, and abatacept.
    id
    OG000
    title
    Abatacept
param Type
MEAN
reporting Status
POSTED
time Frame
Day +100 post-transplant
title
Hematologic and Immunologic Reconstitution
type
SECONDARY
unit Of Measure
cell per microlitre

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice